Key Highlights
- NSPR reported second-quarter 2026 Revenue of $1.8 million, essentially flat year over year and beating the $1.4 million estimate by 28.05 percent, with adjusted EPS of negative $0.17 beating the negative $0.20 estimate by 15 percent.
- International revenue grew 21 percent year over year to $2.1 million, while U.S. revenue was negatively impacted by a $734,000 customer Credit tied to the voluntary recall of the CGuard Prime 135 carotid stent delivery system.
- Gross profit was a loss of $0.8 million, compared with a Gross Profit of $0.3 million a year earlier, driven by the recall-related credit and a $612,000 inventory Impairment charge.
- The company initiated a workforce reduction of almost 20 percent of positions, expected to save approximately $9 million annually, with full cost savings anticipated by the fourth quarter.
Recall Obscures Underlying International Growth
InspireMD, Inc. (NASDAQ:NSPR), a Miami-headquartered medical device company that develops and commercializes the CGuard carotid stent system built on its proprietary MicroNet mesh platform, said its voluntary recall of the CGuard Prime 135 centimeter delivery system, announced at the beginning of May, ceased U.S. commercial sales late in April and required booking a $734,000 credit for unconsumed product already at customer sites. Because these recall-related credits more than offset the company's limited gross U.S. product sales during the quarter, reported U.S. revenue does not reflect the underlying Demand management said remains strong among U.S. physicians awaiting the product's return.
International revenue growth of 21 percent, driven entirely by underlying demand rather than currency effects, continued to reflect physician adoption of the CGuard implant across markets where the product remains commercially available, providing a clearer picture of demand for the technology than the recall-affected U.S. segment.
Multiple Regulatory Catalysts Advance Toward Fourth-Quarter Decisions
The company said discussions with the FDA remain constructive regarding its CGUARDIANS II submission for the CGuard Prime 80 platform used in transcarotid artery revascularization, with management indicating potential approval in the fourth quarter of 2026. A separate submission for the original CGuard platform for carotid artery stenting, clinically proven across more than 75,000 global cases, is also expected to see an FDA decision in the fourth quarter. Should both platforms gain approval, the company would have TCAR and CAS platforms commercially available before year-end, addressing the full scope of the roughly 75,000 annual U.S. stenting procedures.
Because these approval timelines depend on FDA review processes that remain outside the company's direct control, and because management has already adjusted its stated timeline for the original CGuard platform decision from the third to the fourth quarter this year, further shifts in timing remain a meaningful risk to the company's stated relaunch plans.
Design Modifications for Recalled Platform Progress Toward 2027
Management said design modifications to the CGuard Prime 135 delivery system have performed as anticipated in validation and performance testing, with a Pre-Submission dossier already filed with the FDA. The company continues to target a first-half 2027 timeline for U.S. market re-entry of this platform, with potential for an earlier approval depending on the outcome of biocompatibility testing and the FDA's statutory review process. The recently initiated workforce reduction is intended to align the company's cost structure with these near-term regulatory and commercial priorities while preserving commercial readiness for the anticipated relaunch.
Conclusion
InspireMD's second-quarter results illustrate a Business whose reported figures are temporarily distorted by the CGuard Prime 135 recall, even as international growth and multiple advancing regulatory submissions point to underlying demand for the company's carotid stent technology. The timing of FDA decisions on the CGuard Prime 80 and original CGuard platforms, both expected in the fourth quarter, alongside continued progress on the redesigned CGuard Prime 135 delivery system targeted for first-half 2027, will be the primary catalysts determining the pace of the company's U.S. commercial recovery.






Please wait processing your request...